World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 11 March 2024
Main ID:  NCT00235560
Date of registration: 09/09/2005
Prospective Registration: No
Primary sponsor: University Hospital, Toulouse
Public title: Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients LAM-RAPA
Scientific title: Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients. A Study From the Groupe Ouest Est d'étude Des Leucémies Aiguës Myéloïdes (GOELAMS)
Date of first enrolment: June 2005
Target sample size: 50
Recruitment status: Completed
URL:  https://clinicaltrials.gov/ct2/show/NCT00235560
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 2
Countries of recruitment
France
Contacts
Name:     RECHER Christian
Address: 
Telephone:
Email:
Affiliation:  CHU Toulouse
Key inclusion & exclusion criteria

Inclusion Criteria:

- Informed consent

- de novo or secondary LAM (CML excluded) not elligible for intensive chemotherapy.

- Previously untreated

Exclusion Criteria:

- Renal impairment (serum creatinin >2N)

- Hepatic impairment (TGO ou TGP > 5N), une cholestase (Phosphatases Alcalines or
gamma-GT > 5N),bilirubin > 3N

- Blast crisis CML

- Acute Promyelocytic Leukemia.



Age minimum: 60 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Acute Myeloid Leukemia
Intervention(s)
Drug: rapamycin
Primary Outcome(s)
response rate
Secondary Outcome(s)
bioclinical markers of response
tolerability
Secondary ID(s)
0402008
PHRC
GOELAMS
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
French Innovative Leukemia Organisation
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history